Bolt Biotherapeutics
Bolt Biotherapeutics, founded in 2015 by Dr. Edgar G. Engleman, develops innovative tumor-targeted therapies using its proprietary Boltbody™ ISAC platform, focusing on cancers like HER2-positive and Dectin-2 related cancers.
Company Overview
Bolt Biotherapeutics, founded in 2015 by Dr. Edgar G. Engleman of Stanford University, is a biotechnology company that develops tumor-targeted therapies. The company is headquartered in Redwood City, California, and leverages both the innate and adaptive immune systems to address various forms of cancer. Their primary focus is on creating innovative solutions for challenging cancer types.
Founders
Bolt Biotherapeutics was founded by Dr. Edgar G. Engleman in 2015. Dr. Engleman is a notable figure from Stanford University and has been instrumental in establishing the company’s scientific direction. His expertise and vision have been foundational in advancing Bolt Biotherapeutics' mission to develop novel cancer therapies.
Innovative Cancer Therapies
Bolt Biotherapeutics focuses on developing tumor-targeted therapies with a robust pipeline that includes BDC-1001 and BDC-3042. BDC-1001 is currently in clinical development for HER2-positive cancers such as colorectal, endometrial, gastroesophageal, and metastatic breast cancer. BDC-3042 targets cancers like triple-negative breast cancer and clear cell renal cell carcinoma. These therapies utilize Bolt’s proprietary Boltbody™ ISAC platform to enhance treatment efficacy.
Collaborations
Bolt Biotherapeutics actively engages in strategic collaborations to advance its clinical development programs. Notable partnerships include those with Bristol-Myers Squibb and Roche. These collaborations aim to leverage combined expertise and resources to bring innovative cancer therapies to the market more efficiently.
Proprietary Platform
Bolt Biotherapeutics’ proprietary platform, known as Boltbody™ ISAC, is a cornerstone of their therapeutic development. This platform integrates innate and adaptive immune system components to create targeted therapies against various cancers. The Boltbody™ ISAC technology is a critical asset that enhances the efficacy of Bolt’s cancer treatment pipeline.